Business Weekly - Cambridge, UK

HOME News Life Sciences Korean firm enlists help for float

Korean firm enlists help for float

Written by News Desk

Wednesday, 19 March 2008

Bioheart Korea (BHK), a pioneering cell therapy firm with the potential to revolutionise the treatment of heart failure, has become the first South Korean company to float on London’s AIM list thanks to Cambridge Consultants Ltd. The local tech consultancy was contracted to prepare the independent Expert’s Report, which was published as part of the AIM Admission Document on behalf of BHK, validating the science behind its products. BHK not only develops and manufacturers artificial organs, but also has one of the largest state-of-the-art cell medicine production facilities in Asia to harvest adult stem cells for its cell therapy product, Myocell. Set as favorite Bookmark Email This Hits: 258 Trackback(0) TrackBack URI for this entry Comments (0) Subscribe to this comment's feed Write comment This content has been locked. You can no longer post any comment.

 

< Prev		Next >